Measuring personal and functional changes in prostate cancer survivors: Development and validation of the FADE: Data from the TROG 03.04 RADAR trial
Date of this Version
1057-9249 print, 1099-1611 online
There are more survivors of prostate cancer (PCa) than any other cancer . Although there are a number of successful treatments for PCa such as prostatectomy, radiation therapy, hormone therapy or active surveillance (for men with low grade cancer that is monitored until there is evidence of need for curative treatment), there is evidence that each of these carries some adverse symptomatic side effects which last into ‘survivorship’, or at least 5 years post-diagnosis as defined by the American Cancer Society . These symptomatic side effects have been investigated by measures such as the EORTC QLQ PR-25 and associated scales, the National Comprehensive Cancer Network’s Distress Thermometer Screening Tool and the Expanded Prostate Cancer Index Composite for Clinical Practice. Self-report scales that measure anxiety, depression and quality of life are also used when investigating the longer-term effects of PCa treatment upon survivors.
This document is currently not available here.
This document has been peer reviewed.